Zidovudine and the natural history of the acquired immunodeficiency syndrome.
Zidovudine and the natural history of the acquired immunodeficiency syndrome.
复制标题
齐多夫定和获得性免疫缺陷综合征的自然史。
DOI：
10.1056/nejm199105163242006
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Chaisson,RE
中科院分区：
文献类型：
--
作者：
Moore,RD;Hidalgo,J;Sugland,BW;Chaisson,RE
背景和方法我们试图描述1983 - 1989年获得性免疫缺陷综合征（AIDS）患者的生存趋势，并研究齐多夫定使用对AIDS自然史的相对影响以及人口统计学和临床特征。这项纵向、观察性、基于人群的研究使用了来自马里兰州人类免疫缺陷病毒信息系统的数据，该数据库将来自马里兰州艾滋病登记处的信息与公共和私人医疗保健索赔、生命统计数据以及医院、长期护理、结果艾滋病患者诊断后的中位生存期（n = 1028）1987年至1989年诊断的患者比1983年至1985年诊断的患者多140天（450天对310天）。1987年4月以后诊断出艾滋病的714人中（齐多夫定上市后），男性的两年生存率高于女性（P <0.03），45岁以下的人比老年人（P <0.001），在非西班牙裔白人中，艾滋病病毒感染者中，同性性接触者的HIV感染率高于异性性接触者、输血相关者和不常见的HIV感染者（P <0.001）。在所有的分析中，生存期较长的组更有可能接受齐多夫定治疗。接受齐多夫定治疗的患者中位生存期为770天，而从未接受过齐多夫定治疗的患者中位生存期为190天（P <0.001）。通过比例风险分析，齐多夫定治疗是最强相关的因素与改善survival.ConclusionsFor马里兰州居民艾滋病有改善生存自1987年以来。齐多夫定治疗和可能与之相关的其他方面的护理大大提高了生存率。（N Engl J Med 1991; 324：1412 - 6.）
Background and MethodsWe sought to describe the trends in survival from 1983 to 1989 among persons with the acquired immunodeficiency syndrome (AIDS) and to examine the relative effects on the natural history of AIDS of zidovudine use and demographic and clinical characteristics. This longitudinal, observational, population-based study used data from the Maryland Human Immunodeficiency Virus Information System, a data base that links information from the Maryland AIDS Registry with data on public and private health care claims, vital statistics, and hospital, long-term care, and ambulatory care records.ResultsThe median survival after diagnosis among persons with AIDS (n = 1028) was 140 days longer for those given their diagnoses between 1987 and 1989 than for those given their diagnoses between 1983 and 1985 (450 vs. 310 days). Among the 714 persons in whom AIDS was diagnosed after April 1987 (when zidovudine became available), two-year survival was greater among men than women (P<0.03), among persons less than 45 years old than among older persons (P<0.001), among non-Hispanic whites than among minorities (P<0.001), and among persons whose category of human immunodeficiency virus transmission was homosexual contact than among those with heterosexual, transfusion-related, or less common modes of transmission (P<0.02). In all the analyses the groups with the longer survival were more likely to have received zidovudine. The median survival among those who received zidovudine was 770 days, as compared with 190 days among those who never received the drug (P<0.001). By proportional-hazards analysis, zidovudine therapy was the factor most strongly associated with improved survival.ConclusionsFor Maryland residents with AIDS there has been an improvement in survival since 1987. Zidovudine therapy and perhaps other aspects of care associated with it have contributed substantially to the improved survival. (N Engl J Med 1991; 324:1412–6.)
登录
查看更多内容
澳大利亚艾滋病患者齐多夫定治疗效果的影响因素
DOI：
--
发表时间：
1990
期刊：
影响因子：
--
作者：
C. Swanson;D. Cooper
通讯作者：
D. Cooper
治疗可以解释最近艾滋病发病率的下降。
DOI：
--
发表时间：
1990
期刊：
Journal of acquired immune deficiency syndromes
影响因子：
--
作者：
Gail,MH;Rosenberg,PS;Goedert,JJ
通讯作者：
Goedert,JJ
旧金山前 500 名艾滋病患者的生存模式。
影响因子：
6.4
作者：
P. Bacchetti;D. Osmond;R. Chaisson;S. Dritz;G. Rutherford;L. Swig;A. Moss
通讯作者：
A. Moss
全州艾滋病信息系统在卫生服务规划和评估中的开发和应用
DOI：
--
发表时间：
1990
期刊：
影响因子：
--
作者：
J. Hidalgo
通讯作者：
J. Hidalgo
影响因子：
39.2
作者：
FISCHL, MA;RICHMAN, DD;ANDERSON, J
通讯作者：
ANDERSON, J